- Safe Gluten-Free Food List (Safe Ingredients)
- Unsafe Gluten-Free Food List (Unsafe Ingredients)
- Gluten-Free Alcoholic Beverages
- Celiac Disease Symptoms
- The Gluten-Free Diet 101 - A Beginner's Guide to Going Gluten-Free
- Interpretation of Celiac Disease Blood Test Results
- Is Buckwheat Flour Really Gluten-Free?
- Celiac Disease & Gluten Intolerance Research
Celiac Disease & Gluten Intolerance Research
A research team recently conducted an analysis of the relationship between seronegative celiac disease (SNCD) and immunoglobulin deficiencies.
According to the latest press release, aspergillus niger prolyl endoprotease (AN-PEP) efficiently degrades gluten molecules into non-immunogenic peptides. But so what?
What can an isolated tribe of indigenous South Americans who have only recently begun eating wheat tell researchers about celiac disease?
A research team recently looked at the prevalence of autoimmune diseases among patients with non-celiac wheat sensitivity (NCWS), and investigated whether they carry antinuclear antibodies (ANA).
A team of researchers recently conducted an inverse χ2 meta-analysis across ten pediatric-age-of-onset autoimmune diseases.
People with celiac disease have slightly higher risk for contracting pneumonia, especially in the first year after diagnosis.
Some researchers and clinicians suspect a connection between eosinophilic esophagitis (EoE) and celiac disease, but prior studies have shown conflicting results.
For the first time since it was described and named by 1st century Greek physician Aretaeus of Cappadocia, first linked to wheat in the 1940's, and specifically linked to gluten in 1952, scientists have discovered the cause of celiac disease.
Italian researcher Giuseppe Mazzarella offers an examination of the role of effector and suppressor T cells in celiac.
The presence of specific human leukocyte antigen-DQ2 and DQ8 seems to be necessary for celiac disease development, but its usefulness for screening is still uncertain.
A research team recently set out to assess the risk of non-celiac autoimmune disease in first-degree relatives and spouses of people with celiac disease.
Could proprietary antigen-specific nano-particles offer a potential cure for celiac disease? Early results are very positive, say a team of researchers.
Children with celiac disease show an impaired immune response to the hepatitis B vaccine, and neither a gluten-free diet, nor additional vaccine boosters seem to change that, according to research presented at the 33rd Annual Meeting of the European Society for Paediatric Infectious Diseases.
The vast majority of people who follow a gluten-free diet do not have celiac disease or gluten intolerance. Many people who follow a gluten-free diet do so because of perceived health benefits. This includes a number of athletes who feel that the diet improves their energy levels, performance and recovery time.
Currently available digestive enzymes do not fully degrade gluten, and are thus of questionable use for people with celiac disease or gluten intolerance, says a recent study.
A team of researchers recently set out to evaluate the prevalence, diagnostic exclusion of celiac disease and the efficacy of a gluten-free diet (GFD) for patients with self-reported non-gluten sensitivity.
Celiac disease risk is strongly influenced by genetic variation in the major histocompatibility complex region. A new study sheds light on the MHC's connection to celiac disease.
What should be the screening standards for celiac disease in the general population, and in high-risk groups? To gain an answer, a team of researchers recently set out to review medical literature on screening for celiac disease in relation to the current World Health Organization (WHO) criteria for mass screening.
It is well known that fermenting wheat flour with sourdough lactobacilli and fungal proteases reduces the amount of gluten. A team of researchers recently assessed whether patients with celiac disease can safely consume baked goods made from this hydrolyzed kind of wheat flour.
Dr. Falk Pharma and Zedira recently announced the start of phase I clinical trials for the drug candidate ZED1227, a direct acting inhibitor of tissue transglutaminase.